CORCEPT THERAPEUTICS INC (CORT) Stock
6 of the hedge funds AlphaScala tracks reported CORT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $457.50M. Company insiders reported 0 open-market buys and 43 sales on SEC Form 4 in the 90 days to Oct 30, 2026.
Which hedge funds own CORT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 5.26M | $457.50M | -7% |
| D.E. Shaw David Shaw | 883K | $76.78M | -25% |
| Millennium Management Israel Englander | 153K | $13.27M | -73% |
| Citadel Ken Griffin | 109K | $9.49M | -57% |
| Bridgewater Associates Ray Dalio | 58K | $5.01M | +50% |
| Marshall Wace | 6K | $489.4K | -70% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are CORCEPT THERAPEUTICS INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Wilson James N | Director | SELL | 6.7K | $762K |
| Oct 15, 26 | Wilson James N | Director | SELL | 3.0K | $351K |
| Oct 15, 26 | Wilson James N | Director | SELL | 300 | $35K |
| Oct 2, 26 | Maduck Sean | See Remarks | SELL | 15.8K | $1.8M |
| Oct 2, 26 | Maduck Sean | See Remarks | SELL | 8.7K | $1.0M |
| Oct 2, 26 | Lyon Joseph Douglas | See Remarks | SELL | 4.4K | $514K |
| Oct 2, 26 | Lyon Joseph Douglas | See Remarks | SELL | 4.7K | $553K |
| Oct 2, 26 | Vieira Roberto Wandenkolk | President, Oncology | SELL | 1.1K | $126K |
| Oct 2, 26 | Vieira Roberto Wandenkolk | President, Oncology | SELL | 2.1K | $241K |
| Oct 2, 26 | Vieira Roberto Wandenkolk | President, Oncology | SELL | 5.1K | $600K |
SEC Form 4 filings as of Oct 30, 2026 · not updated for 4 days; newer filings may exist
See cluster-buy signals across all tickers →CORT price chart
Powered by TradingViewWhat does CORCEPT THERAPEUTICS INC do?
Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs that modulate cortisol effects to treat severe endocrinologic, metabolic, oncologic, and neurologic disorders. Its flagship product, Korlym, is a cortisol receptor blocker used to control hyperglycemia in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for it. The company advances a pipeline of selective cortisol modulators, including relacorilant, targeting conditions such as hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS), and liver disease. Operating in the health technology sector, specifically pharmaceuticals, Corcept Therapeutics Incorporated addresses unmet needs in rare and serious disorders through innovative therapies that mitigate excess cortisol's adverse impacts. Founded in 1998 and headquartered in Redwood City, California, it plays a key role in advancing treatments for cortisol-related pathologies.